Document is current
Any future updates will be listed below
-
Authors
Isakoglou, Christina https://orcid.org/0000-0003-3803-0400
Haak, Koen V.
Wolfers, Thomas
Floris, Dorothea L.
Llera, Alberto
Oldehinkel, Marianne https://orcid.org/0000-0002-7573-0548
Forde, Natalie J.
Oakley, Bethany F. M.
Tillmann, Julian
Holt, Rosemary J.
Moessnang, Carolin
Loth, Eva https://orcid.org/0000-0001-9458-9167
Bourgeron, Thomas
Baron-Cohen, Simon https://orcid.org/0000-0001-9217-2544
Charman, Tony https://orcid.org/0000-0003-1993-6549
Banaschewski, Tobias https://orcid.org/0000-0003-4595-1144
Murphy, Declan G. M. https://orcid.org/0000-0002-6664-7451
Buitelaar, Jan K. https://orcid.org/0000-0001-8288-7757
Marquand, Andre F.
Beckmann, Christian F.
- License Information
-
More Information
Article History
Received: 27 June 2022
Revised: 26 March 2023
Accepted: 4 July 2023
First Online: 27 July 2023
Competing interests
: TC has received consultancy fees from Roche and book royalties from Guildford Press and Sage. TB served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg, Shire, and Infectopharm, received conference support or speaker’s fees from Lilly, Medice, and Shire, and received royalties from Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press; the present work is unrelated to these relationships. DGMM has been a consultant to and advisory board member for Roche and Servier; he is not an employee of nor stock shareholder in any of these companies. JKB has been a consultant to, advisory board member of, and speaker for Takeda/Shire, Medice, Roche, and Servier; he is not an employee of nor stock shareholder in any of these companies. He has no other financial or material support, including expert testimony, patents, or royalties. CFB is director and shareholder in SBGneuro. The other authors report no biomedical financial interests or potential conflicts of interest.
